Skip to main content
padlock icon - secure page this page is secure

Translating Cancer Biomarker Discoveries to Clinical Tests: What should be Considered?

Buy Article:

$68.00 + tax (Refund Policy)

The use of biomarkers for the diagnosis, prognosis, and monitoring of disease; as well as to guide the choice of therapeutic regimens is predicted to be one of the leading priorities in clinical practice. The sheer complexity of the human cell, including its growth and signaling pathways, has made one of the biggest challenges in the cancer field the identification and characterization of such biomarkers and their translation into informative and reproducible diagnostic/prognostic tests. The increasing amounts of data, generated by experimental methods, challenges researchers to extract biologically applicable information. The authors, who represent academia, industry, and governmental organizations, discuss the current potential of translating cancer biomarker discoveries into suitable clinical tests. This review includes current information based on the latest patents in the cancer biomarker field relating to the different types of biomarkers (genomic, proteomics, epigenetics and microRNAs). It also describes the importance of strong intellectual property protection, current trends in patenting biomarkers, and future intellectual property strategies in the biomarker-related field. Finally, a summary of the recent relevant patentsand primary barriers to the translation of new biomarkers into viable clinical diagnostic tests is presented.





No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: Accuracy; Bioinformatics; Genomic Biomarkers; IP protection; NPV; PPV; biomarker discovery; cancer biomarkers; epigenetics; genomics; miRNA; proteomics; sensitivity; specificity

Document Type: Research Article

Publication date: September 1, 2011

More about this publication?
  • Recent Patents on Biomarkers publishes review and research articles, and guest edited thematic issues on important recent patents on biomarkers. The coverage includes novel biomarkers in basic, medical, environmental, and pharmaceutical research. A selection of important and recent patents on biomarkers is also included in the journal. The journal is essential reading for all researchers involved in biomarker research and discovery. The journal also covers recent research (where patents have been registered) in fast emerging patent biomarker applications; discovery and validation are covered for drug discovery, clinical development and molecular diagnostics.
  • Editorial Board
  • Information for Authors
  • Subscribe to this Title
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more